1-20 of 80
Xin Chen
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Targeting ARPC1B Overcomes Immune Checkpoint Inhibitor Resistance in Glioblastoma by Reversing Protumorigenic Macrophage Polarization

Tianqi Liu, Tao Sun, Xin Chen, Jianqi Wu, Xiaoqian Sun, Xing Liu, Haixu Yan, Qiang Fu, Zirong Fan, Xiangyu Wang, Peng Cheng, Wen Cheng, Anhua Wu
Journal: Cancer Research
Cancer Res (2025) 85 (7): 1236–1252.
https://doi.org/10.1158/0008-5472.CAN-24-2286
Published: 03 April 2025
View articletitled, Targeting ARPC1B Overcomes Immune Checkpoint Inhibitor Resistance in Glioblastoma by Reversing Protumorigenic Macrophage Polarization
Open the PDF for Targeting ARPC1B Overcomes Immune Checkpoint Inhibitor Resistance in Glioblastoma by Reversing Protumorigenic Macrophage Polarization in another window
Includes: Supplementary data
Journal Articles

HBV Remodels PP2A Complexes to Rewire Kinase Signaling in Hepatocellular Carcinoma

Rigney E. Turnham, Adriana Pitea, Gwendolyn M. Jang, Zhong Xu, Huat Chye Lim, Alex L. Choi, John Von Dollen, Rebecca S. Levin, James T. Webber, Elizabeth McCarthy, Junjie Hu, Xiaolei Li, Li Che, Ananya Singh, Alex Yoon, Gary K.L. Chan, Robin K. Kelley, Danielle L. Swaney, Wei Zhang, Sourav Bandyopadhyay, Fabian J. Theis, Manon Eckhardt, Xin Chen, Kevan M. Shokat, Trey Ideker, Nevan J. Krogan, John D. Gordan
Journal: Cancer Research
Cancer Res (2025) 85 (4): 660–674.
https://doi.org/10.1158/0008-5472.CAN-24-0456
Published: 17 February 2025
View articletitled, HBV Remodels PP2A Complexes to Rewire Kinase Signaling in Hepatocellular Carcinoma
Open the PDF for HBV Remodels PP2A Complexes to Rewire Kinase Signaling in Hepatocellular Carcinoma in another window
Includes: Supplementary data
Journal Articles

Abstract PS08-06: A Phase Ib/II Study to Assess the Safety and Efficacy of PM8002 (Anti-PD-L1 x VEGF-A Bispecific Antibody) in Combination with Nab-Paclitaxel for First Line Treatment of Locally Advanced or Metastatic Triple-Negative Breast Cancer

Jiong Wu, Jian Zhang, Zhongsheng Tong, Qingyuan Zhang, Yong-Sheng Wang, Qiao Cheng, Xin Chen, Zhihua Li, Yongmei Yin
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PS08-06.
https://doi.org/10.1158/1538-7445.SABCS23-PS08-06
Published: 02 May 2024
View articletitled, Abstract PS08-06: A Phase Ib/II Study to Assess the Safety and Efficacy of PM8002 (Anti-PD-L1 x VEGF-A Bispecific Antibody) in Combination with Nab-Paclitaxel for First Line Treatment of Locally Advanced or Metastatic Triple-Negative Breast Cancer
Journal Articles

Analysis of Tumor-Associated AXIN1 Missense Mutations Identifies Variants That Activate β-Catenin Signaling

Ruyi Zhang, Shanshan Li, Kelly Schippers, Yunlong Li, Boaz Eimers, Marla Lavrijsen, Ling Wang, Guofei Cui, Xin Chen, Maikel P. Peppelenbosch, Joyce H.G. Lebbink, Ron Smits
Journal: Cancer Research
Cancer Res (2024) 84 (9): 1443–1459.
https://doi.org/10.1158/0008-5472.CAN-23-2268
Published: 02 May 2024
View articletitled, Analysis of Tumor-Associated AXIN1 Missense Mutations Identifies Variants That Activate β-Catenin Signaling
Open the PDF for Analysis of Tumor-Associated AXIN1 Missense Mutations Identifies Variants That Activate β-Catenin Signaling in another window
Includes: Supplementary data
Journal Articles

Abstract CT277: BGB-LC-201 (NCT05635708): A phase 2, open-label, multi-arm study of tislelizumab (TIS; anti-PD-1) in combination with investigational agents +/- chemotherapy as first-line treatment for patients with locally advanced, unresectable, or metastatic non-small cell lung cancer (NSCLC)

George Blumenschein, Benjamin Besse, Justin F. Gainor, DingZhi Huang, Steven Kao, Se-Hoon Lee, Luis Paz-Ares, Xin Chen, Wanyu He, Sridharan Gururangan, Kathy Zhang, Caicun Zhou
Journal: Cancer Research
Cancer Res (2024) 84 (7_Supplement): CT277.
https://doi.org/10.1158/1538-7445.AM2024-CT277
Published: 05 April 2024
View articletitled, Abstract CT277: BGB-LC-201 (NCT05635708): A phase 2, open-label, multi-arm study of tislelizumab (TIS; anti-PD-1) in combination with investigational agents +/- chemotherapy as first-line treatment for patients with locally advanced, unresectable, or metastatic non-small cell lung cancer (NSCLC)
Journal Articles

Abstract 1808: Discovery of highly selective novel MTA-cooperative PRMT5 inhibitors for the treatment of cancers

Wen-Lian Wu, Taishan Hu, Zhilin Deng, Honghai Li, Quanrong Shen, Lei Zhang, Xiaochu Ma, Peihua Sun, Cindy Cheng, Fang Liu, Xin Chen, Ye Hua, Bryan Huang
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 1808.
https://doi.org/10.1158/1538-7445.AM2024-1808
Published: 22 March 2024
View articletitled, Abstract 1808: Discovery of highly selective novel MTA-cooperative PRMT5 inhibitors for the treatment of cancers
Journal Articles

Abstract 630: The role of AKT pathway in β-catenin mutated hepatocellular carcinoma

Xue Wang, Xin Chen
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 630.
https://doi.org/10.1158/1538-7445.AM2024-630
Published: 22 March 2024
View articletitled, Abstract 630: The role of AKT pathway in β-catenin mutated hepatocellular carcinoma
Journal Articles

Abstract 2371: BGB-B167, a first-in-class 4-1BB/CEACAM5 bispecific antibody, exhibits potent in vitro and < for vivo antitumor activity and < for superior safety profile in preclinical models

Zhuo Li, Liang Qu, Xin Chen, Liu Xue, Jie Li, Qi Liu, Jian Sun, Hanzi Sun, Yun Chen, Yuanyuan Xie, Wanyi Wang, Lin Zhu, Penghao Wang, Xiaosui Zhou, Hongjia Hou, Jie Chen, Xinyi Liu, Yilu Zhang, Ning Liu, Xinyi Liang, Shuo Zhang, Xiaoyan Tang, Jing Song, Tong Zhang, Xiaomin Song, Xuesong Liu, Kang Li, Chichi Huang
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 2371.
https://doi.org/10.1158/1538-7445.AM2024-2371
Published: 22 March 2024
View articletitled, Abstract 2371: BGB-B167, a first-in-class 4-1BB/CEACAM5 bispecific antibody, exhibits potent in vitro and &amp;lt; for vivo antitumor activity and &amp;lt; for superior safety profile in preclinical models
Journal Articles

Abstract 140: Distinct pathways regulated by activated β-Catenin and YAP in hepatoblastoma pathogenesis

Weiting Liao, Xin Chen
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 140.
https://doi.org/10.1158/1538-7445.AM2024-140
Published: 22 March 2024
View articletitled, Abstract 140: Distinct pathways regulated by activated β-Catenin and YAP in hepatoblastoma pathogenesis
Journal Articles

Abstract A036: Nanoparticle targeting in platinum-resistant ovarian cancer reveals dual axis of therapeutic vulnerability involving cholesterol uptake and cell redox balance

Yinu Wang, Andrea Calvert, Cardenas Horacio, Fukai Chen, Russell Keathley, Ji-Xin Chen, Shad Thaxton, Daniela Matei
Journal: Cancer Research
Cancer Res (2024) 84 (5_Supplement_2): A036.
https://doi.org/10.1158/1538-7445.OVARIAN23-A036
Published: 04 March 2024
View articletitled, Abstract A036: Nanoparticle targeting in platinum-resistant ovarian cancer reveals dual axis of therapeutic vulnerability involving cholesterol uptake and cell redox balance
Journal Articles

MEX3C-Mediated Decay of SOCS3 mRNA Promotes JAK2/STAT3 Signaling to Facilitate Metastasis in Hepatocellular Carcinoma

Yunyun Xiao, Yue Li, Dongni Shi, Xiaoqing Wang, Shuqin Dai, Muwen Yang, Lingzhi Kong, Boyu Chen, Xinjian Huang, Chuyong Lin, Wenting Liao, Benke Xu, Xin Chen, Lishuai Wang, Xiangfu Chen, Ying Ouyang, Guozhen Liu, Heping Li, Libing Song
Journal: Cancer Research
Cancer Res (2022) 82 (22): 4191–4205.
https://doi.org/10.1158/0008-5472.CAN-22-1203
Published: 15 November 2022
View articletitled, MEX3C-Mediated Decay of SOCS3 mRNA Promotes JAK2/STAT3 Signaling to Facilitate Metastasis in Hepatocellular Carcinoma
Open the PDF for MEX3C-Mediated Decay of SOCS3 mRNA Promotes JAK2/STAT3 Signaling to Facilitate Metastasis in Hepatocellular Carcinoma in another window
Includes: Supplementary data
Journal Articles

Abstract P1-08-19: Utilising artificial intelligence (AI) for analysing multiplex genomic and magnetic resonance imaging (MRI) data to develop multimodality predictive system for personalised neoadjuvant treatment of breast cancer (BC)

Tarek Ma Abdel-Fatah, Graham Ball, Xin Chen, Dalia Mehaisi, Elisabetta Giannotti, Dorothee Auer, Jayakumar Vadakekolathu, Ruizhe Li, Graham Pockley, Stephen Chan
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P1-08-19.
https://doi.org/10.1158/1538-7445.SABCS21-P1-08-19
Published: 15 February 2022
View articletitled, Abstract P1-08-19: Utilising artificial intelligence (AI) for analysing multiplex genomic and magnetic resonance imaging (MRI) data to develop multimodality predictive system for personalised neoadjuvant treatment of breast cancer (BC)
Journal Articles

Abstract 641: Clinical assessment of the bioavailability of venetoclax tablet and powder formulations

Mohamed Badawi, Bo Tong, Xin Chen, Tammy Palenski, Su Young Kim, Divya Samineni, David Hoffman, Rajeev Menon, Ahmed Hamed Salem
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 641.
https://doi.org/10.1158/1538-7445.AM2021-641
Published: 01 July 2021
View articletitled, Abstract 641: Clinical assessment of the bioavailability of venetoclax tablet and powder formulations
Journal Articles

Abstract 1854: A Fc-competent anti-human TIGIT blocking antibody BGB-A1217 elicits strong immune responses and potent anti-tumor efficacy in pre-clinical models

Xin Chen, Liu Xue, Xiao Ding, Qi Liu, Jing Zhang, Lei Jiang, Sha Liu, Hongjia Hou, Qing Zhu, Bin Jiang, Lijie Zhang, Xiaosui Zhou, Jie Ma, Yucheng Li, Wei Jin, Min Wei, Zhirong Shen, Mike Liu, Kang Li, Tong Zhang
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 1854.
https://doi.org/10.1158/1538-7445.AM2021-1854
Published: 01 July 2021
View articletitled, Abstract 1854: A Fc-competent anti-human TIGIT blocking antibody BGB-A1217 elicits strong immune responses and potent anti-tumor efficacy in pre-clinical models
Journal Articles

Abstract 43: Discovery of ARV-110, a first in class androgen receptor degrading PROTAC for the treatment of men with metastatic castration resistant prostate cancer

Lawrence B. Snyder, Taavi K. Neklesa, Xin Chen, Hanqing Dong, Caterina Ferraro, Deborah A. Gordon, Jennifer Macaluso, Jennifer Pizzano, Jing Wang, Ryan R. Willard, Nicholas Vitale, Ron Peck, Marcia Dougan Moore, Craig M. Crews, John Houston, Andrew P. Crew, Ian Taylor
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 43.
https://doi.org/10.1158/1538-7445.AM2021-43
Published: 01 July 2021
View articletitled, Abstract 43: Discovery of ARV-110, a first in class androgen receptor degrading PROTAC for the treatment of men with metastatic castration resistant prostate cancer
Journal Articles

MDMX Recruits UbcH5c to Facilitate MDM2 E3 Ligase Activity and Subsequent p53 Degradation In Vivo

Jing Yang, Aiwen Jin, Jing Han, Xin Chen, Junnian Zheng, Yanping Zhang
Journal: Cancer Research
Cancer Res (2021) 81 (4): 898–909.
https://doi.org/10.1158/0008-5472.CAN-20-0790
Published: 15 February 2021
View articletitled, MDMX Recruits UbcH5c to Facilitate MDM2 E3 Ligase Activity and Subsequent p53 Degradation In Vivo
Open the PDF for MDMX Recruits UbcH5c to Facilitate MDM2 E3 Ligase Activity and Subsequent p53 Degradation In Vivo in another window
Journal Articles

Abstract 5687: Selective, chemically-induced degradation of BRM (SMARCA2) enables in vivo efficacy in BRG1 (SMARCA4)-deficient xenograft tumor models

Michael Berlin, Jennifer Cantley, Jing Wang, Mark Bookbinder, Gregory Cadelina, Emily Chan, Huifen Chen, Xin Chen, Kim Davenport, Tharu Fernando, Debbie Gordon, Brian Hamman, Roy Haskell, Alexey Ishchenko, Donald S. Kirkpatrick, Jonathan Maher, Mark Merchant, John Moffat, Alicia Morgan, An Nguyen, Jennifer Pizzano, Connor Quinn, Christopher M. Rose, Emma Rousseau, Vijay Sethuraman, Leanna Staben, Catherine Wilson, Xiaofen Ye, Fabio Broccatelli, Robert Yauch, Peter S. Dragovich
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 5687.
https://doi.org/10.1158/1538-7445.AM2020-5687
Published: 15 August 2020
View articletitled, Abstract 5687: Selective, chemically-induced degradation of BRM (SMARCA2) enables in vivo efficacy in BRG1 (SMARCA4)-deficient xenograft tumor models
Journal Articles

Abstract P3-07-02: Developing a robust multidimensional molecular, pathological and radiological prognostic index (MPRPI) to evaluate the response to neoadjuvant chemotherapy (NACT) and predict clinical outcome of breast cancer (BC)

Tarek M. a. Abdel-Fatah, Xin Chen, Ruizhe Li, Elisabetta Giannotti, Dorothee Auer, Jennifer Walker, Jun Lim, A. Graham Pockley, Graham Ball, Emad Rakhah, Ian Ellis, Arlene Chan, Stephen Chan
Journal: Cancer Research
Cancer Res (2020) 80 (4_Supplement): P3-07-02.
https://doi.org/10.1158/1538-7445.SABCS19-P3-07-02
Published: 15 February 2020
View articletitled, Abstract P3-07-02: Developing a robust multidimensional molecular, pathological and radiological prognostic index (MPRPI) to evaluate the response to neoadjuvant chemotherapy (NACT) and predict clinical outcome of breast cancer (BC)
Journal Articles

SNAI1 Promotes the Cholangiocellular Phenotype, but not Epithelial–Mesenchymal Transition, in a Murine Hepatocellular Carcinoma Model

Meng Xu, Jingxiao Wang, Zhong Xu, Rong Li, Pan Wang, Runze Shang, Antonio Cigliano, Silvia Ribback, Antonio Solinas, Giovanni Mario Pes, Katja Evert, Haichuan Wang, Xinhua Song, Shu Zhang, Li Che, Rosa Maria Pascale, Diego Francesco Calvisi, Qingguang Liu, Xin Chen
Journal: Cancer Research
Cancer Res (2019) 79 (21): 5563–5574.
https://doi.org/10.1158/0008-5472.CAN-18-3750
Published: 01 November 2019
View articletitled, SNAI1 Promotes the Cholangiocellular Phenotype, but not Epithelial–Mesenchymal Transition, in a Murine Hepatocellular Carcinoma Model
Open the PDF for SNAI1 Promotes the Cholangiocellular Phenotype, but not Epithelial–Mesenchymal Transition, in a Murine Hepatocellular Carcinoma Model in another window
Includes: Supplementary data
Journal Articles

Abstract 3307: Real-world outcomes of first-line pembrolizumab monotherapy for PD-L1-positive (TPS ≥50%) metastatic non-small cell lung cancer (NSCLC)

Vamsidhar Velcheti, Sheenu Chandwani, Xin Chen, M. Catherine Pietanza, Thomas Burke
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 3307.
https://doi.org/10.1158/1538-7445.AM2019-3307
Published: 01 July 2019
View articletitled, Abstract 3307: Real-world outcomes of first-line pembrolizumab monotherapy for PD-L1-positive (TPS ≥50%) metastatic non-small cell lung cancer (NSCLC)